Formycon targets 20% biosimilar development efficiency gain with AI
Formycon launched an AI-enabled eTMF platform to centralize trial master files for its biosimilar clinical programs. Internal assessment targets about 20% efficiency gains.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.